Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Global Blood Therapeutics (GBT) was a biopharmaceutical company focused on the discovery, development, and delivery of life-changing treatments for patients with grievous, underserved blood-based disorders, with an initial focus on sickle cell disease (SCD). Their lead product, Oxbryta® (voxelotor), was the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization. In October 2022, Global Blood Therapeutics was acquired by Pfizer Inc., and its operations and pipeline, including Oxbryta, are now integrated into Pfizer's Rare Disease portfolio. GBT's mission was to transform the treatment and care of SCD.
Served as the central hub for Global Blood Therapeutics' research and development, corporate operations, and strategic management prior to its acquisition by Pfizer.
Located in a prominent biotech hub in South San Francisco, providing access to a rich ecosystem of talent and innovation. The facilities were designed to support both office-based work and laboratory research.
GBT was known for its patient-focused and science-driven culture, with a strong mission to develop innovative treatments for underserved patient communities, particularly those affected by sickle cell disease. The culture emphasized collaboration and a commitment to making a difference in patients' lives.
The South San Francisco headquarters was pivotal to GBT's journey, housing the leadership and core teams that successfully advanced Oxbryta from clinical development to regulatory approval and commercialization, and managed the company's pipeline of potential SCD therapies.
Prior to its acquisition by Pfizer, Global Blood Therapeutics was actively expanding its global presence to address sickle cell disease, a worldwide health issue. Key functions supported globally included conducting multinational clinical trials for its drug candidates, establishing a European headquarters in Switzerland to oversee operations in Europe, engaging with international regulatory bodies for drug approvals, and planning for the commercial launch and distribution of its therapies in key international markets beyond the United States. Their efforts were primarily focused on regions with significant sickle cell disease populations.
171 Oyster Point Blvd, Suite 300
South San Francisco
California
USA
Address: Haldenstrasse 5, CH-6340 Baar, Switzerland
To establish and expand GBT's operational presence in Europe, facilitate engagement with European health authorities and key opinion leaders, and support market access and commercial launch strategies for its treatments for sickle cell disease patients in the region.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Global Blood Therapeutics' leadership includes:
Global Blood Therapeutics has been backed by several prominent investors over the years, including:
Following Pfizer's acquisition of Global Blood Therapeutics, completed in October 2022, the GBT executive team largely transitioned out of their roles as the company and its operations were integrated into Pfizer. This marked the most significant leadership change for GBT. As GBT no longer operates as an independent entity, there have been no executive hires or exits specifically for 'Global Blood Therapeutics' in the last 12 months (e.g., May 2023 - May 2024).
Discover the tools Global Blood Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by Pfizer, Global Blood Therapeutics likely used common corporate email formats. For example, emails were often structured as the first initial followed by the last name, or first name followed by a period and then last name. As GBT is now part of Pfizer, GBT-specific email addresses (e.g., @gbt.com) are no longer active.
[first_initial][last]@gbt.com or [first].[last]@gbt.com
Format
jdoe@gbt.com or jane.doe@gbt.com (historical example)
Example
0 (GBT email domain is no longer in active use post-acquisition)%
Success rate
Pfizer Press Release • October 5, 2022
Pfizer Inc. announced the successful completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for sickle cell disease (SCD)....more
Pfizer Press Release • August 8, 2022
Pfizer Inc. and Global Blood Therapeutics, Inc. announced that the companies have entered into a definitive agreement under which Pfizer will acquire GBT. This acquisition was intended to complement and enhance Pfizer’s more than 30-year heritage in rare hematology....more
GBT Press Release (archived) • June 10, 2022
GBT announced new data presentations on inclacumab, its investigational P-selectin inhibitor, and voxelotor (Oxbryta), its approved therapy for sickle cell disease, at the European Hematology Association (EHA) 2022 Hybrid Congress. The data highlighted the potential of these therapies to address unmet needs in SCD....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Global Blood Therapeutics, are just a search away.